CJC-1295 with DAC: Why Albumin Binding Matters

Learn how an albumin-binding modification changes the research question for a GHRH analogue and how the long-acting form was studied.

What DAC refers to

Drug Affinity Complex, commonly abbreviated DAC, describes the chemical feature associated with the long-acting CJC-1295 design. The development strategy involved binding to albumin, a circulating protein, to change the duration of exposure.

Jetté and colleagues investigated albumin-associated GHRH analogues and identified CJC-1295 in experimental work. This is a chemical and pharmacological distinction, not simply a stronger version of the same product name. A structural change can alter the way a compound is distributed and measured. ^[1]

What the human pharmacology paper measured

Teichman and colleagues studied CJC-1295 in healthy adults, examining its effects on GH and IGF-I secretion over time. That paper is relevant to the long-acting form that was actually investigated. It is not a study of every product labeled CJC-1295. ^[2]

A hormone response shows pharmacodynamic activity under the study conditions. It does not establish a broad clinical benefit, such as improved performance or slowed aging, without appropriate outcome studies addressing those claims.

Duration is part of the interpretation

An exposure lasting longer changes both the measurement window and the questions that need investigation. Endocrine systems contain feedback loops, and prolonged stimulation cannot be understood solely from a single early blood measurement.

When comparing a paper with another analogue, ask whether both compounds share the albumin-binding feature. Also distinguish a measured duration in a specific study from an advertised universal half-life. Species, formulation and measurement method can affect that comparison.

Match a source to a defined molecule

For research material, the sequence and modification should be documented alongside analytical identity. A nominal peptide name or total vial mass cannot establish the presence of the DAC feature.

Use the original source to identify the tested form, population and endpoint. This overview does not provide a regimen or present endocrine stimulation as a health benefit for a reader.

Questions to bring to the evidence

• Was the albumin-binding form used in the cited study?
• Is the claim about hormone secretion or a separately demonstrated clinical outcome?

Sources & further reading

1. Jetté et al. (2005): albumin-binding CJC-1295 researchPrimary preclinical study
2. Teichman et al. (2006): CJC-1295 in healthy adultsPrimary human pharmacology study of the long-acting form